Parent et al., 2022 - Google Patents
A treatment paradigm shift: targeted radionuclide therapies for metastatic castrate resistant prostate cancerParent et al., 2022
View HTML- Document ID
- 9354253071441963367
- Author
- Parent E
- Kase A
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Simple Summary Metastatic prostate cancer has traditionally been treated with a combination of hormonal and chemotherapy regimens. With the recent FDA approval of targeted radionuclide therapeutics, there is now a new class of therapy that is routinely …
- 206010061289 Metastatic neoplasm 0 title abstract description 14
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ruigrok et al. | The future of PSMA-targeted radionuclide therapy: an overview of recent preclinical research | |
| Zhang et al. | PSMA theranostics: current landscape and future outlook | |
| Vahidfar et al. | Theranostic advances in breast cancer in nuclear medicine | |
| Combes et al. | PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer | |
| Fizazi et al. | Health-related quality of life and pain outcomes with [177Lu] Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial | |
| Camus et al. | Indications of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review | |
| Ahmadi Bidakhvidi et al. | Peptide receptor radionuclide therapy targeting the somatostatin receptor: basic principles, clinical applications and optimization strategies | |
| Manafi-Farid et al. | Targeted palliative radionuclide therapy for metastatic bone pain | |
| Plichta et al. | Prostate-specific membrane antigen (PSMA) theranostics for treatment of oligometastatic prostate cancer | |
| Altieri et al. | Bone metastases in neuroendocrine neoplasms: from pathogenesis to clinical management | |
| Mitran et al. | Bispecific GRPR-antagonistic anti-PSMA/GRPR heterodimer for PET and SPECT diagnostic imaging of prostate cancer | |
| Uccelli et al. | 90Y/177Lu-DOTATOC: from preclinical studies to application in humans | |
| Parent et al. | A treatment paradigm shift: targeted radionuclide therapies for metastatic castrate resistant prostate cancer | |
| Mokoala et al. | PSMA theranostics: science and practice | |
| Kolasinska-Ćwikła et al. | A clinical efficacy of PRRT in patients with advanced, nonresectable, paraganglioma-pheochromocytoma, related to SDHx gene mutation | |
| Kaewput et al. | Update of PSMA theranostics in prostate cancer: current applications and future trends | |
| Sanli et al. | 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer | |
| Stenberg et al. | Evaluation of the PSMA-binding ligand 212Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer | |
| Huynh et al. | Copper-67-labeled bombesin peptide for targeted radionuclide therapy of prostate cancer | |
| Merola et al. | Peptide receptor radionuclide therapy (PRRT): innovations and improvements | |
| Filippi et al. | Prognostic and theranostic applications of positron emission tomography for a personalized approach to metastatic castration-resistant prostate cancer | |
| Yordanova et al. | Advances in molecular imaging and radionuclide therapy of neuroendocrine tumors | |
| Cimini et al. | Peptide receptor radionuclide therapy and primary brain tumors: an overview | |
| Bober et al. | Early complications of radioisotope therapy with lutetium-177 and yttrium-90 in patients with neuroendocrine neoplasms—a preliminary study | |
| Yordanova et al. | Combination therapies with PRRT |